Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CSI-109
- Development stage
- Preclinical
- Lead developer
- Curigin
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies
- Administration
- Inhalation
01
Overview
CSI-109 (Csi109) is an investigational bi-specific small interfering RNA (siRNA) therapeutic being developed by Curigin for the treatment of cystic fibrosis. Utilizing Curigin's proprietary bi-specific siRNA platform, CSI-109 is designed to simultaneously target and inhibit the expression of two key genes: ANO1 (anoctamin 1) and MUC5AC (mucin 5AC). By silencing these targets, the therapy aims to address the underlying pathophysiology of cystic fibrosis, particularly mucus hypersecretion and airway obstruction. CSI-109 is formulated for non-viral delivery and is currently in the preclinical stage of development.
02
Targets
MUC5AC (Mucin-5AC)ANO1 (Anoctamin-1)
Beyond the preview
Go deeper on CSI-109.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CSI-109.